PMID- 25725264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1873-5177 (Electronic)
IS  - 0091-3057 (Linking)
VI  - 132
DP  - 2015 May
TI  - Beneficial effect of honokiol on lipopolysaccharide induced anxiety-like behavior 
      and liver damage in mice.
PG  - 79-87
LID - S0091-3057(15)00056-8 [pii]
LID - 10.1016/j.pbb.2015.02.015 [doi]
AB  - Anxiety disorders are commonly occurring co-morbid neuropsychiatric disorders 
      with chronic inflammatory conditions such as live damage. Numerous studies 
      revealed that peripheral inflammation, oxidative stress and brain derived 
      neurotrophic factor (BDNF) play important roles in the pathophysiology of anxiety 
      disorders. Honokiol (HNK) is a polyphenol, possessing multiple biological 
      activities including antioxidant, anti-inflammatory, anxiolytic, antidepressant 
      and hepatoprotection. The present study was designed to investigate the effect of 
      HNK, in lipopolysaccharide (LPS)-induced anxiety-like behavior and liver damage 
      in mice. Mice (n=6-10/group) were pre-treated with different doses of HNK (2.5 
      and 5mg/kg; i.p.) for two days, and challenged with saline or LPS (0.83mg/kg; 
      i.p.) on third day. Anxiety-like behavior was monitored using elevated plus maze 
      (EPM) and open field test (OFT). Animals were sacrificed to evaluate various 
      biochemical parameters in plasma and liver. HNK pre-treatment provided 
      significant (P<0.01) protection against LPS-induced reduction in body weight, 
      food and water intake in mice. HNK at higher dose significantly (P<0.05) 
      attenuated LPS-induced anxiety-like behavior by increasing the number of entries 
      and time spent in open arm in EPM test, and by increasing the frequency in 
      central zone in OFT. HNK pre-treatment ameliorated LPS-induced peripheral 
      inflammation by reducing plasma IL-1beta, IL-6, TNF-alpha level, and also improved the 
      plasma BDNF level, prevented liver damage via attenuating transaminases (AST, 
      ALT), liver oxidative stress and TNF-alpha activity in LPS challenged mice. In 
      conclusion, the current investigation suggests that HNK provided beneficial 
      effect against LPS-induced anxiety-like behavior and liver damage which may be 
      governed by inhibition of cytokines production, oxidative stress and depletion of 
      plasma BDNF level. Our result suggests that HNK could be a therapeutic approach 
      for the treatment of anxiety and other neuropsychiatric disorders associated with 
      inflammation and oxidative stress.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Sulakhiya, Kunjbihari
AU  - Sulakhiya K
AD  - Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National 
      Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 
      781032, India. Electronic address: niperkunj@gmail.com.
FAU - Kumar, Parveen
AU  - Kumar P
AD  - Laboratory of Molecular Pharmacology and Toxicology, Department of Pharmacology 
      and Toxicology, National Institute of Pharmaceutical Education and Research 
      (NIPER), Guwahati, Assam 781032, India.
FAU - Gurjar, Satendra S
AU  - Gurjar SS
AD  - Department of Biotechnology, National Institute of Pharmaceutical Education and 
      Research (NIPER), Guwahati, Assam 781032, India.
FAU - Barua, Chandana C
AU  - Barua CC
AD  - Department of Pharmacology and Toxicology, College of Veterinary Science, Assam 
      Agricultural University, Khanapara, Guwahati, Assam 781032, India.
FAU - Hazarika, Naba K
AU  - Hazarika NK
AD  - Department of Microbiology, Gauhati Medical College, Guwahati, Assam 781032, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20150226
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
OTO - NOTNLM
OT  - Anxiety
OT  - Honokiol
OT  - Inflammation
OT  - Lipopolysaccharide
OT  - Oxidative stress
EDAT- 2015/03/01 06:00
MHDA- 2015/03/01 06:01
CRDT- 2015/03/01 06:00
PHST- 2014/09/28 00:00 [received]
PHST- 2015/02/11 00:00 [revised]
PHST- 2015/02/16 00:00 [accepted]
PHST- 2015/03/01 06:00 [entrez]
PHST- 2015/03/01 06:00 [pubmed]
PHST- 2015/03/01 06:01 [medline]
AID - S0091-3057(15)00056-8 [pii]
AID - 10.1016/j.pbb.2015.02.015 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 2015 May;132:79-87. doi: 10.1016/j.pbb.2015.02.015. Epub 
      2015 Feb 26.